November 1, 2017 (Vol. 37, No. 19)
Eight new recombinant antigens are available for in vitro diagnostic (IVD), manufacturing, and research applications. The recombinant Parvovirus NS1, VP1, VP2, VP2-VLP, PepA (VP1 unique), PepB (VP2 C-term), PepC (VP1 N-term), and PepD (VP1 C-term) have all been expressly designed for use as integral components within solid-phase enzyme immunoassay (EIA) test procedures, including ELISA. All of these antigens are sourced from an Escherichia coli-derived recombinant protein and exhibit exceptional purity levels as a result of unique chromatography techniques. They all feature an outstanding shelf-life stability claim of 10 years from the date of manufacture and are offered in a standard-sized 1.0-mg filled vial, with larger, bulk configurations also available.